Form 8-K - Current report:
SEC Accession No. 0001193125-26-316766
Filing Date
2026-07-27
Accepted
2026-07-27 06:06:03
Documents
14
Period of Report
2026-07-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d31466d8k.htm   iXBRL 8-K 54719
2 EX-2.1 d31466dex21.htm EX-2.1 519155
3 EX-10.1 d31466dex101.htm EX-10.1 74353
4 EX-99.1 d31466dex991.htm EX-99.1 25852
  Complete submission text file 0001193125-26-316766.txt   960262

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20260726.xsd EX-101.SCH 3187
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20260726_lab.xml EX-101.LAB 17993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20260726_pre.xml EX-101.PRE 11266
17 EXTRACTED XBRL INSTANCE DOCUMENT d31466d8k_htm.xml XML 3639
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 261202749
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)